ESA Nations Ask What Comes After Ariane

LONDON—Competing schemes to take Western Europe into a new era in extraterrestrial transportation are posing a conundrum for the continent's space planners. At the heart of the debate is just how ambitious Western Europe wants to be in its next generation of space launchers, together with whether the countries involved can put aside their contrasting approaches and agree on a common goal. At issue is the next big transportation project for the 13-nation European Space Agency (ESA), the Par

Written byPeter Marsh
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

At issue is the next big transportation project for the 13-nation European Space Agency (ESA), the Paris-based, intergovernmental body that coordinates Western Europe's space activities. The agency, which was formed in 1975 and spends about $1.5 billion a year, developed the French-inspired Ariane, a conventional, expendable rocket for launching satellites. Thanks largely to the shuttle problems in the United States, the rocket is likely to be the main launch vehicle for the western world's satellites over the next two years.

ESA has already decided to spend nearly $3 billion over the next decade to build a more powerful version of Ariane, the so-called Ariane-5, to lift heavier satellites. But the arguments about what comes next have already begun.

France, as the world's third biggest spender on space technology after the United States and the Soviet Union, is the dominant nation. within ESA. She has proposed spending up to $4.5 billion ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies